EUCTR2017-003495-31-BE进行中（未招募）1 期
A randomized, Investigator-and patient-blind, placebo-controlled, parallel group first in human and proof of concept study to evaluate the safety, tolerability, and efficacy of CLL442 in patients with Cutaneous Squamous Cell Carcinoma in situ (SCCis) - Not applicable
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •- Written informed consent has been obtained.
- •- Male and female patients, age = 18 to = 90 years (at the time of the screening visit).
- •- A primary, clinically diagnosed and histologically confirmed cutaneous SCC in situ lesion, with or without the involvement of the follicular unit, and histologically diagnosed within 30 days of the screening visit. The post-biopsy residual SCCis lesion must be visually evident and at least 3 mm in either length or width.
- •- The lesion must be located in a place easily accessible for topical application by the patient or their caregiver, excluding the genitals, perianal area, sub-ungual area, eyelids, ear and must be >1 cm away from the eyes and mouth.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •- Evidence of dermatological disease or histological evidence of a
- •confounding skin condition in the treatment area, including but not limited to BCC, worse level/grade of SCC, rosacea, psoriasis, atopic dermatitis, eczema, xeroderma pigmentosa, verrucous lesions or any other tumor in the biopsy specimen. Lesions with atypical histology such as: spindle cell SCC, acantholytic SCC, clear cell SCC, adenosquamous SCC, desmoplastic SCC or lesions that have been present for a short time and have been fast growing.
- •- Treatment of the target SCCis lesion within 8 weeks of screening visit by any of the following treatments: Liquid nitrogen, Photochemotherapy (PUVA), Long wave ultra violet radiation (UVB light), surgical excision or curettage within 1 cm of target lesion.; Systemic retinoids.; Ionizing radiation or interlesional injections or; Undergone a facial resurfacing procedure, i.e., chemical peel, laser resurfacing, dermabrasion, within the target lesion;
- •- Treatment with the following topical agents within the 4 weeks prior to the screening visit: Levulanic acid, 5-fluorouracil, corticosteroids,
- •retinoids, diclofenac, hyaluronic acid, imiquimod.
- •- History of recurrence of the target SCCis lesion.
- •- Systemic use of immunosuppressive drugs within 4 weeks prior to screening visit or during the treatment period - Photodynamic therapy or immunomodulators, cytotoxic drugs, or interferon/interferon inducers within 4 weeks prior to study entry or expected during the study.
- •- Women of child-bearing potential, unless they are using at least basic methods of contraception during dosing of investigational drug.
- •- Pregnant or nursing (lactating) women.
研究者
相似试验
进行中（未招募）
1 期
Study of LLG783 in patients with peripheral artery disease (PAD) and intermittent claudication.EUCTR2017-000706-37-DEovartis Pharma AG46
进行中（未招募）
1 期
Study of safety, tolerability, pharmacokinetics and pharmacodynamics of QBW251 in subjects with bronchiectasisMedDRA version: 23.0Level: LLTClassification code 10083611Term: Non-cystic fibrosis bronchiectasisSystem Organ Class: 100000004855BronchiectasisEUCTR2019-002840-26-GBovartis Pharma AG72
进行中（未招募）
1 期
Study of LIK066 in overweight and obese women with polycystic ovary syndromepolycystic ovary syndromeMedDRA version: 20.0Level: LLTClassification code 10036050Term: Polycystic ovarySystem Organ Class: 100000004872EUCTR2017-001373-16-DEovartis Pharma AG29
进行中（未招募）
1 期
Study of safety, tolerability, pharmacokinetics and pharmacodynamics of QBW251 in subjects with bronchiectasisMedDRA version: 23.0Level: LLTClassification code 10083611Term: Non-cystic fibrosis bronchiectasisSystem Organ Class: 100000004855BronchiectasisEUCTR2019-002840-26-DEovartis Pharma AG72
进行中（未招募）
1 期
Study to assess the efficacy and safety of CJM112 in patients with inadequately controlled severe asthmaInadequately controlled moderate to severe asthmaMedDRA version: 20.0 Level: PT Classification code 10003553 Term: Asthma System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2017-000205-21-DKovartis Pharma AG110